769 patents
Page 11 of 39
Utility
ENTPD2 Antibodies, Combination Therapies, and Methods of Using the Antibodies and Combination Therapies
3 Nov 22
Provided herein are methods of treating cancer using an antibody or antigen-binding fragments thereof that specifically bind to human ENTPD2 protein, and compositions comprising these antibodies or antigen-binding fragments for use in the treatment of cancer.
Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
Filed: 17 Sep 20
Utility
Antibody-cytokine Engrafted Proteins and Methods of Use for Immune Related Disorders
3 Nov 22
The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor.
Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
Filed: 18 Jul 22
Utility
Sulphonamides and Compositions Thereof for Treating Conditions Associated with NLRP Activity
27 Oct 22
Shankar VENKATRAMAN, Shomir GHOSH, William R. ROUSH, Dong-Ming SHEN, Jason KATZ, Hans Martin SEIDEL
Filed: 12 Oct 18
Utility
Methods of Treating or Selecting a Treatment for a Subject Resistant to TNF Inhibitor Using a NLRP3 Antagonist
27 Oct 22
Provided herein are methods of treating a subject that include administering a therapeutically effective amount of an NLPR3 antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having a cell that has an elevated level of NLRP3 inflammasome activity and/or expression as compared to a reference level.
Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William R. ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
Filed: 2 Jul 19
Utility
1,2,4-OXADIAZOLE Derivatives As Liver X Receptor Agonists
27 Oct 22
Kelly D. BOSS, Yi FAN, Alec Nathanson FLYER, Declan HARDY, Zhihong HUANG, Kathryn Taylor LINKENS, Jon Christopher LOREN, Fupeng MA, Valentina MOLTENI, Duncan SHAW, Jeffrey SMITH, Catherine Fooks SOLOVAY
Filed: 6 Jun 22
Utility
Treatment of Liver Disease or Disorder Comprising Actrii Receptor Antagonists
27 Oct 22
The present disclosure provides an ActRII antagonist, e.g., the ActRIIA and/or ActRIIB antagonist, e.g., an anti-ActRII receptor antibody or antigen-binding fragment thereof, e.g., bimagrumab, for treating or preventing liver disease or disorder in a subject in need thereof.
Laura COLEMAN, C. Daniel MEYERS, Ronenn ROUBENOFF, Estelle TRIFILIEFF
Filed: 1 Sep 20
Utility
Combination Therapy with ENTPD2 and CD73 Antibodies
27 Oct 22
Provided herein are combinations comprising an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to ENTPD2 (e.g., human ENTPD2 protein), and an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to CD73 (e.g., human CD73 protein), and methods of using these combinations.
Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
Filed: 17 Sep 20
Utility
Methods of Treatment Using Omalizumab
27 Oct 22
The present disclosure relates to methods for modifying the course of a disease or disorder involving Treg cells dysfunctioning, in particular in patients having an allergic disease or condition.
XAVIER JAUMONT, Oscar PALOMARES
Filed: 31 Aug 20
Utility
Pharmaceutical Compositions Comprising Alpelisib
20 Oct 22
The present invention relates to dispersible tablets comprising the compound (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-I, I-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceuti-cally acceptable salt thereof.
Michaela Anna Maria Bock, Frantz Elbaz, Charu Kochhar, Doris Stingelin
Filed: 29 Jun 22
Utility
Use of an MDM2 Inhibitor for the Treatment of Myelofibrosis
20 Oct 22
The invention relates to the use of an MDM2 inhibitor in the treatment of myelofibrosis (MF).
Asa Eliasson, Nelson Guerreiro, Christophe Meille, Hans Menssen, K Gary J Vanasse, Monika Wroclawska
Filed: 14 Sep 20
Utility
Treatment Comprising the Use of FXR Agonists
20 Oct 22
The invention provides, FXR agonists for the treatment of a condition or a disease associated with mitochondrial dysfunction, e.g. a mitochondrial disease, in a subject in need thereof.
Dominique BREES, Patricia LOPEZ, Iwona KSIAZEK
Filed: 29 Sep 20
Utility
Methods and Compositions for Treatment of Cartilage Damage and Arthritis
20 Oct 22
The invention provides methods and compositions for the treatment of cartilage damage or arthritis.
Jörg Goldhahn, Kristen Johnson, Celeste Scotti, Igor Vostiar
Filed: 6 May 22
Utility
Dosing Regimen and Combination Therapies for Multispecific Antibodies Targeting B-cell Maturation Antigen
20 Oct 22
The present disclosure relates to dosing regimens, formulations, and combinations comprising a multispecific antibody having at least binding specificity towards B cell maturation antigen (BCMA) and a T-cell engaging arm; and methods of using such multispecific antibodies in the treatment or prevention of disease, such as, cancer.
Kimberly AARDALEN, Aida ABUJOUB, John BLANKENSHIP, Anuradha CONNOR, Mirek DOSTALEK, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU, K. Gary J. VANASSE
Filed: 22 Jun 20
Utility
a Method for Preventing Human Virus Associated Disorders In Patients
20 Oct 22
The disclosure relates to methods of preventing an human virus-associated disorder, in particular EBV-associated disorder, as well as to a method of controlling EBV load in a subject, in particular in a subject being at risk of developing such a disorder like solid organ transplantation patients.
TINA RUBIC-SCHNEIDER, Elisabetta TRAGGIA, Peter ULRICH
Filed: 11 Sep 19
Utility
Protein Kinase C Inhibitors for Treatment of Uveal Melanoma
13 Oct 22
The present disclosure relates to use of a protein kinase C (PKC) inhibitor in the treatment or prevention of proliferative diseases.
Vesselina Cooke, Michael Scott Visser, Andrew Wylie, Padmaja Yerramilli-Rao, Xu Zhu
Filed: 23 Jun 22
Utility
Sustained Delivery of Angiopoetin-like 3 Polypeptides
13 Oct 22
Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.
Christopher M. ADAMS, Myriam APRIL, Tanzina FAZAL, Cornelia Jutta FORSTER, Nicole GERWIN, Edward Charles HALL, Jean-Baptiste Georges Armand LANGLOIS, Cameron Chuck-munn LEE
Filed: 26 May 22
Utility
1,3-SUBSTITUTED Cyclobutyl Derivatives and Uses Thereof
13 Oct 22
Donglei LIU, Julien PAPILLON, Stefan PEUKERT, James J. POWERS
Filed: 24 Mar 22
Utility
5,6-FUSED-BICYCLIC Compounds and Compositions for the Treatment of Parasitic Diseases
13 Oct 22
Jan Jiricek, Isabelle K. Lerario, Fang Liang, Xiaodong Liu, Valentina Molteni, Advait Suresh Nagle, Shuyi Pearly NG, Maxim Ratnikov, Jeffrey M. Smith, Yongping Xie
Filed: 13 May 22
Utility
Use of the Anti-p-selectin Antibody Crizanlizumab for Treating Sickle Cell Nephropathy and Chronic Kidney Disease Associated with Sickle Cell Disease
13 Oct 22
The invention relates to a method of treating chronic kidney disease due to sickle cell nephropathy in a patient in need of such treatment, comprising administering a pharmaceutically effective amount of an anti-P-selectin antibody or a binding fragment thereof to said patient and related invention embodiments (uses, methods, pharmaceutical preparations and use in the preparation of pharmaceutical preparations).
Kenneth ATAGA, Laurie DEBONNETT, Vimal DEREBAIL, Guangyang HAN, Adlette INATI, Julie KANTER, Jeffrey LEBENSBURGER, Santosh SARAF, Claire SHARPE, Pablo BARTOLUCCI, Miona STANKOVIC
Filed: 6 Aug 20
Utility
Novel Eukaryotic Cells and Methods for Recombinantly Expressing a Product of Interest
13 Oct 22
The disclosure pertains to novel eukaryotic cell suitable for recombinant production of a product of interest, wherein the genome of the host cell is altered so that the effect of protein FAM60A is impaired in said cell, e.g. by reducing or eliminating functional expression of gene FAM60A thereby improving the stability characteristics.
Thomas JOSTOCK, Holger LAUX, Anett RITTER
Filed: 21 Dec 21